Evoke Pharma (STU:EV00) Debt-to-Asset : 0.71 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma Debt-to-Asset?

Evoke Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Evoke Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4.59 Mil. Evoke Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €6.48 Mil. Evoke Pharma's debt to asset for the quarter that ended in Dec. 2023 was 0.71.

Evoke Pharma Debt-to-Asset Historical Data

The historical data trend for Evoke Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Debt-to-Asset Chart

Evoke Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.56

0.47

0.43

0.71

Evoke Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.43	0.51	0.56	0.64	0.71

Competitive Comparison of Evoke Pharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evoke Pharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's Debt-to-Asset falls into.

Evoke Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Evoke Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	4.585)	/	6.482
	=	0.71

Evoke Pharma's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	4.585)	/	6.482
	=	0.71

Evoke Pharma (STU:EV00) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Evoke Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Evoke Pharma (STU:EV00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

EVOK:USA

Address

420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075

Website

https://www.evokepharma.com

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines